Drugs / E/C/F/TDF
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01815736 Comparator | Mar 2013 → Mar 2015 | HIV infectious disease | Gilead Sciences | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E/C/F/TDF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01815736 ↗ |
| Route | Oral | “150/150/200/300 mg FDC tablet administered orally once daily” NCT01815736 ↗ |